Nutra Pharma Corp.’s (NPHC) 7-year Marketing Exclusivity for Pediatric MS RPI-78M is more than just Luck
In September 2015, Nutra Pharma Corporation (OTCQB: NPHC), in what CEO Rik Deitsch has called “the most substantial event in the history of our drug discovery efforts,” was granted Orphan Status for RPI-78M for the treatment of Juvenile or Pediatric Multiple Sclerosis (MS). Orphan Status for a drug brings many advantages. It gives the sponsoring company tax credits that may amount to as much as 50% of the development costs attributable to qualified clinical testing. This could include remuneration to employees to supervise, carry out and support qualified clinical testing activities. Orphan Status can also mean a reduction or exemption…